Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2003-10-01
2008-09-23
Lucas, Zachariah (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S007100, C424S207100, C424S208100
Reexamination Certificate
active
07427468
ABSTRACT:
The present invention provides methods of using antibodies that bind a TSG101 protein to inhibit or reduce viral production. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV infection. The invention further provides methods of detecting viral infected cells using TSG101 antibodies.
REFERENCES:
patent: 2002/0177207 (2002-11-01), Sugiyama et al.
patent: 2003/0171318 (2003-09-01), Morham et al.
patent: WO 02/072790 (2002-09-01), None
patent: WO 2004/039311 (2004-05-01), None
Leller Ma et al. “Passive immunity in prevention and treatment of infectious diseases”. Clin Microbiol Rev. Oct. 2000;13(4):602-14.
Trkola A te al. “Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies” Nature Medicine 11, 615-622 (2005).
Senior K “Budding new HIV therapies?” Drug Discovery Today, vol. 6, No. 23, pp. 1184-1186 (2001).
Supplementary Partial European Search Report dated Nov. 17, 2005.
Oh, et al., Negative regulation of cell growth and differentiation by TSG101 through association with p21Cip1/WAF1, Proc. Natl. Acad. Sci. USA, vol. 99, No. 8, pp. 5430-5435, 2002.
Krempler, et al., “Targeted Deletion of theTsg101Gene Results in Cell Cycle Arrest at G1/S and p53-independent Cell Death”, Jour. Biol. Chem., vol. 277, No. 45, pp. 43216-41223, 2002.
Wagner, et al., “Tsg101 Is Essential for Cell Growth, Proliferation, and Cell Survival of Embryonic and Adult Tissues”, Mol. and Cell Biol., vol. 23, No. 1, pp. 150-162, 2003.
Bishop, et al., “Mammalian call E vps proteins recognize ubiquitin and act in the removal of endosomal protein-ubiquitin conjugates”, Jour. Cell Biol., vol. 157, No. 1, pp. 91-101, 2002.
Li, et al., “A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control”, Proc. Natl. Acad. Sci. USA, vol. 98, No. 4, pp. 1619-1624, 2001.
Ruland, et al., “p53 Accumulation, defective cell proliferation, and early embryonic lethality in mice lackingtsg101”, Proc. Natl. Acad. Sci. USA, vol. 98, No. 4, pp. 1859-1864, 2001.
Moyret-Lalle, et al., “p53 Induction Prevents Accumulation of Aberrant Transcripts in Cancer Cells”, Cancer Research, vol. 61, pp. 486-488, 2001.
Göttlinger, et al., “Effect of mutations affecting the p6gagprotein on human immunodeficiency virus particle release”, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 3195-3199, 1991.
Huang, et al., “p6GagIs Required for Particle Production from Full-Length Human Immunodeficiency Virus Type 1 Molecular Clones Expressing Protease”, Jour. Virol., vol. 69, No. 11, pp. 6810-6818, 1995.
Parent, et al., “Positionally Independent and Exchangeable Late Budding Functions of the Rous Sarcoma Virus and Human Immunodeficiency Virus Gag Proteins”, Jour. Virol. vol. 69, No. 9, pp. 5455-5460, 1995.
Yuan, et al., “Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle”, The EMBO Jour., vol. 18, No. 17, pp. 4700-4710, 1999.
Yasuda, et al., “A Proline-Rich Motif (PPPY) in the Gag Polyprotein of Mason-Pfizer Monkey Virus Plays a Maturation-Independent Role in Virion Release”, Jour. Virol. vol. 72, No. 5, pp. 4095-4103, 1998.
Puffer, et al., “Equine Infectious Anemia Virus Utilizes a YXXL Motif within the Late Assembly Domain of the Gag p9 Protein”, Jour. Virol., vol. 71, No. 9, pp. 6541-6546, 1997.
Wills, et al., “An Assembly Domain of the Rous Sarcoma Virus Gag Protein Required Late in Budding”, Jour. Virol., vol. 68, No. 10, pp. 6605-6618, 1994.
VerPlank, et al., “Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55Gag”, Proc. Natl. Acad. Sci. USA, vol. 98, No. 14, pp. 7724-7729, 2001.
Garrus, et al., “Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding”, Cell, vol. 107, pp. 55-65, 2001.
Martin-Serrano, et al., “HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress”, Nature Medicine, vol. 7, No. 12, pp. 1313-1319, 2001.
Pornillos, et al., “Structure and functional interactions of the Tsg101 UEV domain”, The EMBO Jour., vol. 21, No. 10, pp. 2397-2406, 2002.
Demirov, et al., “Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function”, Proc. Natl. Acad. Sci. USA, vol. 99, No. 2, pp. 955-960, 2002.
Patnaik, et al. “Ubiquitin is part of the retrovirus budding machinery”, Proc. Natl. Acad. Sci. USA, vol. 97, No. 24, pp. 13069-13074, 2000.
Schubert, et al., “Proteasome inhibition interferes with Gag polyprotein processing, release, and maturation of HIV-1 and HIV-2”, Proc. Natl. Acad. Sci. USA, vol. 97, No. 24, pp. 13057-13062, 2000.
Strack, et al., “A role for ubiquitin ligase recruitment in retrovirus release”, Proc. Natl. Acad. Sci. USA, vol. 97, No. 24, pp. 13063-13068, 2000.
Bishop, et al., “TSG101/Mammalian VPS23 and Mammalian VPS28 Interact Directly and Are Recruited to VPS4-induced Endosomes”, Jour. Cell Biol., vol. 276, No. 15, pp. 11735-11742, 2001.
Little, et al., “Antiretroviral-Drug Resistance Among Patients Recently Infected With HIV”, New. Eng. Jour. Med., vol. 347, No. 6, pp. 385-394, 2002.
Functional Genetics, Inc.
Kelber Steven B.
Lucas Zachariah
Peng Bo
LandOfFree
Anti-TSG101 antibodies and their uses for treatment of viral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-TSG101 antibodies and their uses for treatment of viral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-TSG101 antibodies and their uses for treatment of viral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981856